Medicare Enrolled
Dr. Eric Santos, M.D.
Hematology & Oncology · Grand Rapids, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Santos from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Santos?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Santos
Dr. Eric Santos is a hematology & oncology specialist in Grand Rapids, MI, with 18 years of NPI registration. Based on federal Medicare data, Dr. Santos performed 23,294 Medicare services across 1,185 unique beneficiaries.
Between the years covered by Open Payments, Dr. Santos received a total of $11,277 from 36 pharmaceutical and/or device companies across 123 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Santos is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 18% volume in MI
$11,277 industry payments
Medicare Practice Summary
Medicare Utilization ↗23,294
Medicare services
Top 18% in MI for hematology & oncology
1,185
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,294 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,550 | $0 | $3 |
| Lanreotide injection, 1 mg A 1 mg injection of lanreotide medication administered into the body. |
7,080 | $43 | $103 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,856 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,150 | $1 | $31 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
709 | $2 | $4 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
355 | $11 | $34 |
| Injection, potassium chloride, per 2 meq | 325 | $0 | $0 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
314 | $8 | $15 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
296 | $93 | $292 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
287 | $8 | $26 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
285 | $10 | $35 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
243 | $94 | $189 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
210 | $62 | $133 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
189 | $91 | $180 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
159 | $77 | $70 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
134 | $1 | $1 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
111 | $10 | $38 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
111 | $47 | $142 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
110 | $20 | $47 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
109 | $21 | $66 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
104 | $16 | $57 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
75 | $93 | $220 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
67 | $2 | $4 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
60 | $15 | $41 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
56 | $9 | $26 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
46 | $39 | $100 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
43 | $24 | $84 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
32 | $26 | $83 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
29 | $129 | $264 |
| New patient office visit, complex (60-74 min) | 23 | $149 | $324 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
23 | $1 | $2 |
| Blood or blood product transfusion The administration of whole blood or specific blood components into a patient's bloodstream. |
22 | $26 | $95 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
22 | $45 | $151 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
21 | $134 | $304 |
| Hospital discharge management, 30+ min This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge. |
20 | $88 | $236 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
17 | $4 | $13 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
15 | $61 | $126 |
| Hepatitis B core antibody test A blood test that measures the level of antibodies to the hepatitis B core antigen. This test helps determine if a person has been infected with the hepatitis B virus. |
12 | $12 | $30 |
| Hepatitis B surface antibody test A blood test that measures the level of antibodies against the hepatitis B surface antigen. This test is used to check for immunity to hepatitis B or to verify the effectiveness of the hepatitis B vaccine. |
12 | $11 | $27 |
| Hepatitis B surface antigen test A blood test that uses an immunoassay technique to detect the presence of the hepatitis B surface antigen. This test identifies whether the hepatitis B virus is currently present in the body. |
12 | $10 | $26 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.1% high complexity
88.2% medium
8.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,277
Total received (2018-2024)
Avg $1,611/year across 7 years
Top 16% in MI for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
123
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$7,004 (62.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,261 (37.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$230
2023
$328
2022
$712
2021
$3,252
2020
$39
2019
$6,264
2018
$453
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ARRAY BIOPHARMA INC
$51
Regeneron Healthcare Solutions, Inc.
$49
Novartis Pharmaceuticals Corporation
$39
Genentech USA, Inc.
$29
Ipsen Biopharmaceuticals, Inc
$26
Mirati Therapeutics, Inc.
$20
E.R. Squibb & Sons, L.L.C.
$17
Top 3 companies account for 60.2% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$3,906
GENZYME CORPORATION
$3,173
AstraZeneca UK Limited
$1,559
Foundation Medicine, Inc.
$470
E.R. Squibb & Sons, L.L.C.
$360
ARRAY BIOPHARMA INC
$238
Gilead Sciences, Inc.
$223
Novartis Pharmaceuticals Corporation
$191
PFIZER INC.
$180
Regeneron Healthcare Solutions, Inc.
$116
Catalyst OrthoScience
$104
Genentech USA, Inc.
$104
Ipsen Biopharmaceuticals, Inc
$63
Merck Sharp & Dohme Corporation
$58
Amgen Inc.
$55
Pharmacyclics LLC, An AbbVie Company
$48
Eisai Inc.
$48
Bayer HealthCare Pharmaceuticals Inc.
$45
Takeda Pharmaceuticals U.S.A., Inc.
$37
Celgene Corporation
$32
GlaxoSmithKline, LLC.
$32
Lilly USA, LLC
$24
Mirati Therapeutics, Inc.
$20
EUSA Pharma (US) LLC
$18
Incyte Corporation
$17
Merck Sharp & Dohme LLC
$17
Seattle Genetics, Inc.
$16
Pharmacyclics LLC, an AbbVie Company
$16
JAZZ PHARMACEUTICALS INC.
$16
Mylan Institutional Inc.
$15
Janssen Biotech, Inc.
$13
Agios Pharmaceuticals, Inc.
$13
Astellas Pharma US Inc
$13
AbbVie, Inc.
$12
Puma Biotechnology, Inc.
$12
Novo Nordisk Inc
$11
Top 3 companies account for 76.6% of all-time payments
Associated products mentioned in payments ›
Alecensa · BLENREP · BRAFTOVI · CALQUENCE · Catalyst Total CSR · Columvi · ELIQUIS · Epclusa · FOUNDATIONONE · FOUNDATIONONE CDX · Fulphila · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · MVASI · NERLYNX · NINLARO · NovoSeven RT · OPDIVO · Onivyde · PIQRAY · PROMACTA · Reblozyl · Revlimid · SOMATULINE DEPOT · SUTENT · Stivarga · Sylvant · TAGRISSO · TECENTRIQ · TIBSOVO · VERZENIO · VOTRIENT · VYXEOS · Venclexta · XALKORI · XTANDI · Xofigo · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (62%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
23
Per 100K population
3.5
County median income
$80,390
Nearest hospital
SPECTRUM HEALTH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Santos is a mixed practice specialist, with above-average Medicare volume (top 18% in MI), with consulting-driven industry engagement in the top 16% of MI peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Santos experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Santos performed 8,550 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Santos receive payments from pharmaceutical companies?
Yes. Dr. Santos received a total of $11,277 from 36 companies across 123 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Santos's costs compare to other hematology & oncology specialists in Grand Rapids?
Dr. Santos's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Santos) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Grand Rapids
Browse hematology & oncology specialists in Grand Rapids ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MI
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MI
Which MI hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
AstraZeneca UK Limited Payments to Doctors
See all physicians who received payments from AstraZeneca UK Limited.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology